RxDoctor Payments Data

Toni Murphy, DO

Endocrinology, Diabetes & Metabolism · West Seneca, NYNPI 1003862897

Payments from drug & device makers

$39,112in general payments, 2019–2025

Across 583 payments — averaging $67.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$22K
  • AstraZeneca$8K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$1K
  • Amgen$1K
  • Medtronic$723
  • plus $5K from 36 others

What the payments were for

  • Speaking & faculty fees$27,26770%
  • Travel & lodging$5671%
  • Food & beverage$11,25429%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,112 in reported general payments places this provider in the 85th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York

Medicare billing

Part B allowed, 2024
$35,734
Medicare patients
206
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide133$191,371
MounjaroTirzepatide84$124,854
JardianceEmpagliflozin121$122,145
OzempicSemaglutide57$70,035
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog34$38,954
Lantus SolostarInsulin Glargine,hum.Rec.Anlog155$26,642
Humalog Kwikpen U-100Insulin Lispro75$24,886
Soliqua 100-33Insulin Glargine/Lixisenatide15$18,155
Insulin Lispro Kwikpen U-100Insulin Lispro42$12,440
FarxigaDapagliflozin Propanediol13$11,872
SynthroidLevothyroxine Sodium151$10,473
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$9,666
Levothyroxine Sodium546$9,416
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$7,586
V-Go 20Sub-Q Insulin Device, 20 Unit11$5,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog$1,317$320,701234 claims
Boehringer IngelheimJardiance$1,019$122,145121 claims
Novo NordiskOzempic, Novolog$85$74,11072 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$22,062$19,29827 claims
AstraZenecaFarxiga$8,238$11,87213 claims
AbbVieSynthroid$571$10,473151 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$289$9,416546 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

Other endocrinology, diabetes & metabolism in West Seneca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →